These factors reinforce the need for individualized treatment plans rather than broad, unsupervised use
You also have the option to pick your price," with various prices ranging from $0.50 to $18.37
The EGCG group showed a significant reduction in total fibroid volume, a 32.4% reduction in fibroid-specific symptom severity, and a significant decrease in average menstrual blood loss (from 71 mL/month to 45 mL/month) compared to the control group, in which fibroid volume increased by 24.3%. Proposed mechanisms: EGCG inhibits the proliferation of leiomyoma cells, induces apoptosis, and suppresses ER expression
BCBS of Vermont no longer covers any GLP-1 receptor agonists FDA-approved for weight loss as of January 1, 2026
After spending $100 million on the drugs for weight loss in 2024 and seeing sizable operating losses to boot, Point32Health announced in May that it would stop automatically covering the drugs for obesity starting in 2026